nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—ovarian cancer	0.21	1	CrCtD
Epirubicin—Topoisomerase Inhibitors—Topotecan—ovarian cancer	0.131	0.447	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—ovarian cancer	0.106	0.363	CiPCiCtD
Epirubicin—uterine cancer—ovarian cancer	0.0627	0.366	CtDrD
Epirubicin—breast cancer—ovarian cancer	0.0618	0.361	CtDrD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—ovarian cancer	0.0556	0.19	CiPCiCtD
Epirubicin—testicular cancer—ovarian cancer	0.0466	0.272	CtDrD
Epirubicin—Valrubicin—Doxorubicin—ovarian cancer	0.0443	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—ovarian cancer	0.0443	0.333	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—ovarian cancer	0.0443	0.333	CrCrCtD
Epirubicin—DHCR7—Doxorubicin—ovarian cancer	0.0311	0.272	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—ovarian cancer	0.0311	0.272	CbGbCtD
Epirubicin—AURKA—Doxorubicin—ovarian cancer	0.0311	0.272	CbGbCtD
Epirubicin—ABCC1—Paclitaxel—ovarian cancer	0.00649	0.0568	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—ovarian cancer	0.00631	0.0553	CbGbCtD
Epirubicin—ABCC1—Docetaxel—ovarian cancer	0.00469	0.0411	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—ovarian cancer	0.0035	0.0306	CbGbCtD
Epirubicin—CHD1—myometrium—ovarian cancer	0.000577	0.0352	CbGeAlD
Epirubicin—Daunorubicin—NR5A1—ovarian cancer	0.000562	0.626	CrCbGaD
Epirubicin—AURKA—myometrium—ovarian cancer	0.000465	0.0284	CbGeAlD
Epirubicin—CHD1—uterine cervix—ovarian cancer	0.000449	0.0274	CbGeAlD
Epirubicin—CHD1—decidua—ovarian cancer	0.000428	0.0261	CbGeAlD
Epirubicin—CHD1—endometrium—ovarian cancer	0.000406	0.0248	CbGeAlD
Epirubicin—CHD1—gonad—ovarian cancer	0.000376	0.023	CbGeAlD
Epirubicin—CHD1—uterus—ovarian cancer	0.000374	0.0229	CbGeAlD
Epirubicin—AURKA—uterine cervix—ovarian cancer	0.000362	0.0221	CbGeAlD
Epirubicin—YWHAG—myometrium—ovarian cancer	0.000357	0.0218	CbGeAlD
Epirubicin—CHD1—female reproductive system—ovarian cancer	0.000336	0.0206	CbGeAlD
Epirubicin—AURKA—endometrium—ovarian cancer	0.000327	0.02	CbGeAlD
Epirubicin—CHD1—bone marrow—ovarian cancer	0.000317	0.0194	CbGeAlD
Epirubicin—CHD1—female gonad—ovarian cancer	0.000306	0.0187	CbGeAlD
Epirubicin—CHD1—vagina—ovarian cancer	0.000304	0.0186	CbGeAlD
Epirubicin—AURKA—gonad—ovarian cancer	0.000303	0.0185	CbGeAlD
Epirubicin—DHCR7—uterine cervix—ovarian cancer	0.000303	0.0185	CbGeAlD
Epirubicin—AURKA—uterus—ovarian cancer	0.000301	0.0184	CbGeAlD
Epirubicin—YWHAG—uterine cervix—ovarian cancer	0.000278	0.017	CbGeAlD
Epirubicin—CHD1—testis—ovarian cancer	0.000271	0.0166	CbGeAlD
Epirubicin—AURKA—female reproductive system—ovarian cancer	0.000271	0.0166	CbGeAlD
Epirubicin—PLA2G4A—myometrium—ovarian cancer	0.000266	0.0163	CbGeAlD
Epirubicin—YWHAG—decidua—ovarian cancer	0.000265	0.0162	CbGeAlD
Epirubicin—AURKA—bone marrow—ovarian cancer	0.000256	0.0156	CbGeAlD
Epirubicin—DHCR7—gonad—ovarian cancer	0.000254	0.0155	CbGeAlD
Epirubicin—TOP2A—myometrium—ovarian cancer	0.000253	0.0155	CbGeAlD
Epirubicin—YWHAG—endometrium—ovarian cancer	0.000251	0.0153	CbGeAlD
Epirubicin—AURKA—female gonad—ovarian cancer	0.000247	0.0151	CbGeAlD
Epirubicin—AURKA—vagina—ovarian cancer	0.000245	0.015	CbGeAlD
Epirubicin—YWHAG—gonad—ovarian cancer	0.000233	0.0142	CbGeAlD
Epirubicin—YWHAG—uterus—ovarian cancer	0.000231	0.0141	CbGeAlD
Epirubicin—DHCR7—female reproductive system—ovarian cancer	0.000227	0.0139	CbGeAlD
Epirubicin—AURKA—Chlorambucil—Melphalan—ovarian cancer	0.00022	0.255	CbGdCrCtD
Epirubicin—AURKA—testis—ovarian cancer	0.000219	0.0134	CbGeAlD
Epirubicin—DHCR7—bone marrow—ovarian cancer	0.000214	0.0131	CbGeAlD
Epirubicin—YWHAG—female reproductive system—ovarian cancer	0.000208	0.0127	CbGeAlD
Epirubicin—PLA2G4A—uterine cervix—ovarian cancer	0.000207	0.0127	CbGeAlD
Epirubicin—DHCR7—female gonad—ovarian cancer	0.000206	0.0126	CbGeAlD
Epirubicin—DHCR7—vagina—ovarian cancer	0.000205	0.0125	CbGeAlD
Epirubicin—PLA2G4A—decidua—ovarian cancer	0.000197	0.0121	CbGeAlD
Epirubicin—TOP2A—uterine cervix—ovarian cancer	0.000197	0.012	CbGeAlD
Epirubicin—CHD1—lymph node—ovarian cancer	0.000197	0.012	CbGeAlD
Epirubicin—YWHAG—bone marrow—ovarian cancer	0.000196	0.012	CbGeAlD
Epirubicin—YWHAG—female gonad—ovarian cancer	0.000189	0.0116	CbGeAlD
Epirubicin—YWHAG—vagina—ovarian cancer	0.000188	0.0115	CbGeAlD
Epirubicin—UGT2B7—female reproductive system—ovarian cancer	0.000188	0.0115	CbGeAlD
Epirubicin—TOP2A—decidua—ovarian cancer	0.000187	0.0115	CbGeAlD
Epirubicin—PLA2G4A—endometrium—ovarian cancer	0.000187	0.0114	CbGeAlD
Epirubicin—DHCR7—testis—ovarian cancer	0.000183	0.0112	CbGeAlD
Epirubicin—TOP2A—endometrium—ovarian cancer	0.000178	0.0109	CbGeAlD
Epirubicin—YWHAG—testis—ovarian cancer	0.000168	0.0103	CbGeAlD
Epirubicin—TOP2A—uterus—ovarian cancer	0.000164	0.01	CbGeAlD
Epirubicin—AURKA—lymph node—ovarian cancer	0.000159	0.00969	CbGeAlD
Epirubicin—PLA2G4A—female reproductive system—ovarian cancer	0.000155	0.00948	CbGeAlD
Epirubicin—AURKA—Irinotecan—Topotecan—ovarian cancer	0.000153	0.177	CbGdCrCtD
Epirubicin—ABCC1—myometrium—ovarian cancer	0.000152	0.0093	CbGeAlD
Epirubicin—UGT2B7—testis—ovarian cancer	0.000152	0.00927	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—ovarian cancer	0.000146	0.00895	CbGeAlD
Epirubicin—Daunorubicin—CYP1B1—ovarian cancer	0.000144	0.161	CrCbGaD
Epirubicin—PLA2G4A—female gonad—ovarian cancer	0.000141	0.00863	CbGeAlD
Epirubicin—PLA2G4A—vagina—ovarian cancer	0.00014	0.00858	CbGeAlD
Epirubicin—TOP2A—bone marrow—ovarian cancer	0.000139	0.00851	CbGeAlD
Epirubicin—TOP2A—female gonad—ovarian cancer	0.000134	0.0082	CbGeAlD
Epirubicin—TOP2A—vagina—ovarian cancer	0.000133	0.00815	CbGeAlD
Epirubicin—DHCR7—lymph node—ovarian cancer	0.000133	0.00811	CbGeAlD
Epirubicin—PLA2G4A—testis—ovarian cancer	0.000125	0.00765	CbGeAlD
Epirubicin—YWHAG—lymph node—ovarian cancer	0.000122	0.00744	CbGeAlD
Epirubicin—TOP2A—testis—ovarian cancer	0.000119	0.00727	CbGeAlD
Epirubicin—ABCC1—uterine cervix—ovarian cancer	0.000118	0.00724	CbGeAlD
Epirubicin—Doxorubicin—CYP1B1—ovarian cancer	0.000117	0.13	CrCbGaD
Epirubicin—ABCC1—decidua—ovarian cancer	0.000113	0.0069	CbGeAlD
Epirubicin—ABCC1—endometrium—ovarian cancer	0.000107	0.00655	CbGeAlD
Epirubicin—ABCC1—uterus—ovarian cancer	9.87e-05	0.00603	CbGeAlD
Epirubicin—PLA2G4A—lymph node—ovarian cancer	9.08e-05	0.00555	CbGeAlD
Epirubicin—TOP2A—lymph node—ovarian cancer	8.62e-05	0.00527	CbGeAlD
Epirubicin—CHD1—Idarubicin—Doxorubicin—ovarian cancer	8.42e-05	0.0973	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—ovarian cancer	8.42e-05	0.0973	CbGdCrCtD
Epirubicin—ABCC1—female gonad—ovarian cancer	8.08e-05	0.00494	CbGeAlD
Epirubicin—ABCC1—vagina—ovarian cancer	8.03e-05	0.00491	CbGeAlD
Epirubicin—ABCC1—testis—ovarian cancer	7.16e-05	0.00438	CbGeAlD
Epirubicin—TOP2A—Docetaxel—Paclitaxel—ovarian cancer	6.84e-05	0.079	CbGdCrCtD
Epirubicin—TOP2A—Irinotecan—Topotecan—ovarian cancer	5.85e-05	0.0676	CbGdCrCtD
Epirubicin—ABCC1—lymph node—ovarian cancer	5.19e-05	0.00317	CbGeAlD
Epirubicin—TOP2A—Vindesine—Vinorelbine—ovarian cancer	4.35e-05	0.0502	CbGdCrCtD
Epirubicin—Daunorubicin—ABCB1—ovarian cancer	4.14e-05	0.0461	CrCbGaD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—ovarian cancer	3.41e-05	0.0394	CbGdCrCtD
Epirubicin—Doxorubicin—ABCB1—ovarian cancer	3.36e-05	0.0374	CrCbGaD
Epirubicin—AURKA—Idarubicin—Doxorubicin—ovarian cancer	2.77e-05	0.032	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—ovarian cancer	2.77e-05	0.032	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinorelbine—ovarian cancer	2.35e-05	0.0271	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vinorelbine—ovarian cancer	1.89e-05	0.0218	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—ovarian cancer	1.06e-05	0.0122	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—ovarian cancer	1.06e-05	0.0122	CbGdCrCtD
Epirubicin—Chest pain—Paclitaxel—ovarian cancer	8.29e-06	0.000185	CcSEcCtD
Epirubicin—Arthralgia—Paclitaxel—ovarian cancer	8.29e-06	0.000185	CcSEcCtD
Epirubicin—Myalgia—Paclitaxel—ovarian cancer	8.29e-06	0.000185	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.27e-06	0.0005	CbGpPWpGaD
Epirubicin—Anxiety—Paclitaxel—ovarian cancer	8.26e-06	0.000184	CcSEcCtD
Epirubicin—Face oedema—Doxorubicin—ovarian cancer	8.26e-06	0.000184	CcSEcCtD
Epirubicin—Erythema—Docetaxel—ovarian cancer	8.25e-06	0.000184	CcSEcCtD
Epirubicin—Malnutrition—Docetaxel—ovarian cancer	8.25e-06	0.000184	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—SOD1—ovarian cancer	8.25e-06	0.000499	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	8.23e-06	0.000184	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	8.22e-06	0.000497	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PPP2R1A—ovarian cancer	8.21e-06	0.000496	CbGpPWpGaD
Epirubicin—Nausea—Topotecan—ovarian cancer	8.2e-06	0.000183	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	8.2e-06	0.000496	CbGpPWpGaD
Epirubicin—Discomfort—Paclitaxel—ovarian cancer	8.19e-06	0.000183	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	8.17e-06	0.000494	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TYMS—ovarian cancer	8.15e-06	0.000493	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	8.14e-06	0.000492	CbGpPWpGaD
Epirubicin—Cardiac arrest—Doxorubicin—ovarian cancer	8.13e-06	0.000182	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CDKN1B—ovarian cancer	8.12e-06	0.000491	CbGpPWpGaD
Epirubicin—Dry mouth—Paclitaxel—ovarian cancer	8.11e-06	0.000181	CcSEcCtD
Epirubicin—Mood swings—Doxorubicin—ovarian cancer	8.1e-06	0.000181	CcSEcCtD
Epirubicin—Diarrhoea—Vinorelbine—ovarian cancer	8.08e-06	0.00018	CcSEcCtD
Epirubicin—Dysgeusia—Docetaxel—ovarian cancer	8.08e-06	0.00018	CcSEcCtD
Epirubicin—Ataxia—Doxorubicin—ovarian cancer	8.04e-06	0.00018	CcSEcCtD
Epirubicin—Nausea—Melphalan—ovarian cancer	8.03e-06	0.000179	CcSEcCtD
Epirubicin—Confusional state—Paclitaxel—ovarian cancer	8.01e-06	0.000179	CcSEcCtD
Epirubicin—Blood creatinine increased—Doxorubicin—ovarian cancer	8.01e-06	0.000179	CcSEcCtD
Epirubicin—Back pain—Docetaxel—ovarian cancer	7.98e-06	0.000178	CcSEcCtD
Epirubicin—Dehydration—Doxorubicin—ovarian cancer	7.95e-06	0.000178	CcSEcCtD
Epirubicin—Anaphylactic shock—Paclitaxel—ovarian cancer	7.95e-06	0.000177	CcSEcCtD
Epirubicin—Oedema—Paclitaxel—ovarian cancer	7.95e-06	0.000177	CcSEcCtD
Epirubicin—Muscle spasms—Docetaxel—ovarian cancer	7.93e-06	0.000177	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.93e-06	0.000479	CbGpPWpGaD
Epirubicin—Liver function test abnormal—Doxorubicin—ovarian cancer	7.9e-06	0.000176	CcSEcCtD
Epirubicin—Infection—Paclitaxel—ovarian cancer	7.89e-06	0.000176	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—ovarian cancer	7.85e-06	0.000475	CbGpPWpGaD
Epirubicin—Dry skin—Doxorubicin—ovarian cancer	7.84e-06	0.000175	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.82e-06	0.000473	CbGpPWpGaD
Epirubicin—Shock—Paclitaxel—ovarian cancer	7.82e-06	0.000175	CcSEcCtD
Epirubicin—Dizziness—Vinorelbine—ovarian cancer	7.81e-06	0.000174	CcSEcCtD
Epirubicin—Orthostatic hypotension—Doxorubicin—ovarian cancer	7.81e-06	0.000174	CcSEcCtD
Epirubicin—Abdominal pain upper—Doxorubicin—ovarian cancer	7.81e-06	0.000174	CcSEcCtD
Epirubicin—Nervous system disorder—Paclitaxel—ovarian cancer	7.79e-06	0.000174	CcSEcCtD
Epirubicin—Hypokalaemia—Doxorubicin—ovarian cancer	7.78e-06	0.000174	CcSEcCtD
Epirubicin—Thrombocytopenia—Paclitaxel—ovarian cancer	7.78e-06	0.000174	CcSEcCtD
Epirubicin—Tachycardia—Paclitaxel—ovarian cancer	7.75e-06	0.000173	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CCND1—ovarian cancer	7.75e-06	0.000468	CbGpPWpGaD
Epirubicin—Breast disorder—Doxorubicin—ovarian cancer	7.73e-06	0.000173	CcSEcCtD
Epirubicin—Skin disorder—Paclitaxel—ovarian cancer	7.72e-06	0.000172	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	7.7e-06	0.000172	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	7.7e-06	0.000172	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—PPP1CC—ovarian cancer	7.68e-06	0.000465	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—BRIP1—ovarian cancer	7.68e-06	0.000465	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Paclitaxel—ovarian cancer	7.68e-06	0.000171	CcSEcCtD
Epirubicin—Nasopharyngitis—Doxorubicin—ovarian cancer	7.65e-06	0.000171	CcSEcCtD
Epirubicin—Anaemia—Docetaxel—ovarian cancer	7.63e-06	0.00017	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	7.61e-06	0.00046	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—AKT1—ovarian cancer	7.58e-06	0.000458	CbGpPWpGaD
Epirubicin—Anorexia—Paclitaxel—ovarian cancer	7.57e-06	0.000169	CcSEcCtD
Epirubicin—Gastritis—Doxorubicin—ovarian cancer	7.57e-06	0.000169	CcSEcCtD
Epirubicin—Muscular weakness—Doxorubicin—ovarian cancer	7.54e-06	0.000168	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	7.54e-06	0.000168	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—PPP1CC—ovarian cancer	7.53e-06	0.000456	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—BRIP1—ovarian cancer	7.53e-06	0.000456	CbGpPWpGaD
Epirubicin—Vomiting—Vinorelbine—ovarian cancer	7.51e-06	0.000168	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL2—ovarian cancer	7.5e-06	0.000453	CbGpPWpGaD
Epirubicin—Rash—Vinorelbine—ovarian cancer	7.45e-06	0.000166	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.44e-06	0.00045	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.44e-06	0.00045	CbGpPWpGaD
Epirubicin—Dermatitis—Vinorelbine—ovarian cancer	7.44e-06	0.000166	CcSEcCtD
Epirubicin—Abdominal distension—Doxorubicin—ovarian cancer	7.44e-06	0.000166	CcSEcCtD
Epirubicin—Hypotension—Paclitaxel—ovarian cancer	7.42e-06	0.000166	CcSEcCtD
Epirubicin—Headache—Vinorelbine—ovarian cancer	7.4e-06	0.000165	CcSEcCtD
Epirubicin—Syncope—Docetaxel—ovarian cancer	7.4e-06	0.000165	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	7.39e-06	0.000447	CbGpPWpGaD
Epirubicin—Influenza—Doxorubicin—ovarian cancer	7.39e-06	0.000165	CcSEcCtD
Epirubicin—Dysphagia—Doxorubicin—ovarian cancer	7.39e-06	0.000165	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—ovarian cancer	7.39e-06	0.000165	CcSEcCtD
Epirubicin—Leukopenia—Docetaxel—ovarian cancer	7.39e-06	0.000165	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—BIRC5—ovarian cancer	7.33e-06	0.000443	CbGpPWpGaD
Epirubicin—Eosinophilia—Doxorubicin—ovarian cancer	7.32e-06	0.000163	CcSEcCtD
Epirubicin—Palpitations—Docetaxel—ovarian cancer	7.29e-06	0.000163	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—ovarian cancer	7.27e-06	0.000439	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—PIK3CA—ovarian cancer	7.26e-06	0.000439	CbGpPWpGaD
Epirubicin—Loss of consciousness—Docetaxel—ovarian cancer	7.25e-06	0.000162	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—ovarian cancer	7.25e-06	0.000162	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	7.24e-06	0.000162	CcSEcCtD
Epirubicin—DHCR7—Metabolism—CAV1—ovarian cancer	7.22e-06	0.000437	CbGpPWpGaD
Epirubicin—Cough—Docetaxel—ovarian cancer	7.2e-06	0.000161	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—ovarian cancer	7.2e-06	0.000161	CcSEcCtD
Epirubicin—ABCC1—Disease—PPP1CC—ovarian cancer	7.19e-06	0.000435	CbGpPWpGaD
Epirubicin—Insomnia—Paclitaxel—ovarian cancer	7.19e-06	0.00016	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	7.16e-06	0.000433	CbGpPWpGaD
Epirubicin—Convulsion—Docetaxel—ovarian cancer	7.15e-06	0.00016	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MAPK3—ovarian cancer	7.14e-06	0.000432	CbGpPWpGaD
Epirubicin—Paraesthesia—Paclitaxel—ovarian cancer	7.13e-06	0.000159	CcSEcCtD
Epirubicin—Hypertension—Docetaxel—ovarian cancer	7.12e-06	0.000159	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—ovarian cancer	7.11e-06	0.000159	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TERT—ovarian cancer	7.1e-06	0.000429	CbGpPWpGaD
Epirubicin—Dyspnoea—Paclitaxel—ovarian cancer	7.08e-06	0.000158	CcSEcCtD
Epirubicin—Somnolence—Paclitaxel—ovarian cancer	7.06e-06	0.000158	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.03e-06	0.000425	CbGpPWpGaD
Epirubicin—Chest pain—Docetaxel—ovarian cancer	7.03e-06	0.000157	CcSEcCtD
Epirubicin—Myalgia—Docetaxel—ovarian cancer	7.03e-06	0.000157	CcSEcCtD
Epirubicin—Arthralgia—Docetaxel—ovarian cancer	7.03e-06	0.000157	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—ovarian cancer	7.02e-06	0.000157	CcSEcCtD
Epirubicin—Nausea—Vinorelbine—ovarian cancer	7.02e-06	0.000157	CcSEcCtD
Epirubicin—Dyspepsia—Paclitaxel—ovarian cancer	6.99e-06	0.000156	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	6.98e-06	0.000156	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—ovarian cancer	6.95e-06	0.00042	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.91e-06	0.000418	CbGpPWpGaD
Epirubicin—Neutropenia—Doxorubicin—ovarian cancer	6.91e-06	0.000154	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—ovarian cancer	6.91e-06	0.000154	CcSEcCtD
Epirubicin—Decreased appetite—Paclitaxel—ovarian cancer	6.91e-06	0.000154	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.9e-06	0.000417	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYTB—ovarian cancer	6.89e-06	0.000416	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	6.88e-06	0.000416	CbGpPWpGaD
Epirubicin—Dry mouth—Docetaxel—ovarian cancer	6.87e-06	0.000153	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	6.87e-06	0.000153	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.86e-06	0.000153	CcSEcCtD
Epirubicin—Fatigue—Paclitaxel—ovarian cancer	6.85e-06	0.000153	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—ovarian cancer	6.83e-06	0.000152	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MAPK1—ovarian cancer	6.8e-06	0.000411	CbGpPWpGaD
Epirubicin—Constipation—Paclitaxel—ovarian cancer	6.79e-06	0.000152	CcSEcCtD
Epirubicin—Pain—Paclitaxel—ovarian cancer	6.79e-06	0.000152	CcSEcCtD
Epirubicin—Confusional state—Docetaxel—ovarian cancer	6.79e-06	0.000152	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.78e-06	0.00041	CbGpPWpGaD
Epirubicin—Photosensitivity reaction—Doxorubicin—ovarian cancer	6.75e-06	0.000151	CcSEcCtD
Epirubicin—Oedema—Docetaxel—ovarian cancer	6.73e-06	0.00015	CcSEcCtD
Epirubicin—Anaphylactic shock—Docetaxel—ovarian cancer	6.73e-06	0.00015	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	6.73e-06	0.000407	CbGpPWpGaD
Epirubicin—Weight increased—Doxorubicin—ovarian cancer	6.73e-06	0.00015	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—DOK1—ovarian cancer	6.7e-06	0.000405	CbGpPWpGaD
Epirubicin—Infection—Docetaxel—ovarian cancer	6.69e-06	0.000149	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—ovarian cancer	6.69e-06	0.000149	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.68e-06	0.000404	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Doxorubicin—ovarian cancer	6.67e-06	0.000149	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—ovarian cancer	6.63e-06	0.000148	CcSEcCtD
Epirubicin—Shock—Docetaxel—ovarian cancer	6.63e-06	0.000148	CcSEcCtD
Epirubicin—Nervous system disorder—Docetaxel—ovarian cancer	6.6e-06	0.000147	CcSEcCtD
Epirubicin—Thrombocytopenia—Docetaxel—ovarian cancer	6.59e-06	0.000147	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	6.59e-06	0.000398	CbGpPWpGaD
Epirubicin—Drowsiness—Doxorubicin—ovarian cancer	6.59e-06	0.000147	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—ovarian cancer	6.59e-06	0.000147	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—ovarian cancer	6.59e-06	0.000147	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CG—ovarian cancer	6.58e-06	0.000398	CbGpPWpGaD
Epirubicin—Tachycardia—Docetaxel—ovarian cancer	6.57e-06	0.000147	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CCND1—ovarian cancer	6.57e-06	0.000397	CbGpPWpGaD
Epirubicin—Feeling abnormal—Paclitaxel—ovarian cancer	6.55e-06	0.000146	CcSEcCtD
Epirubicin—Skin disorder—Docetaxel—ovarian cancer	6.54e-06	0.000146	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	6.53e-06	0.000146	CcSEcCtD
Epirubicin—Gastrointestinal pain—Paclitaxel—ovarian cancer	6.5e-06	0.000145	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—ovarian cancer	6.48e-06	0.000145	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—ovarian cancer	6.46e-06	0.000144	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.46e-06	0.00039	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	6.45e-06	0.00039	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	6.45e-06	0.00039	CbGpPWpGaD
Epirubicin—Stomatitis—Doxorubicin—ovarian cancer	6.42e-06	0.000143	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—ovarian cancer	6.42e-06	0.000143	CcSEcCtD
Epirubicin—Anorexia—Docetaxel—ovarian cancer	6.42e-06	0.000143	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—ovarian cancer	6.41e-06	0.000143	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—ovarian cancer	6.41e-06	0.000143	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MAPK3—ovarian cancer	6.39e-06	0.000386	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	6.37e-06	0.000385	CbGpPWpGaD
Epirubicin—Sweating—Doxorubicin—ovarian cancer	6.32e-06	0.000141	CcSEcCtD
Epirubicin—Urticaria—Paclitaxel—ovarian cancer	6.31e-06	0.000141	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PPP1CC—ovarian cancer	6.3e-06	0.000381	CbGpPWpGaD
Epirubicin—Hypotension—Docetaxel—ovarian cancer	6.29e-06	0.00014	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—ovarian cancer	6.28e-06	0.00014	CcSEcCtD
Epirubicin—Abdominal pain—Paclitaxel—ovarian cancer	6.28e-06	0.00014	CcSEcCtD
Epirubicin—Body temperature increased—Paclitaxel—ovarian cancer	6.28e-06	0.00014	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.25e-06	0.000378	CbGpPWpGaD
Epirubicin—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.23e-06	0.000139	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—ovarian cancer	6.22e-06	0.000139	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—ovarian cancer	6.21e-06	0.000376	CbGpPWpGaD
Epirubicin—Sinusitis—Doxorubicin—ovarian cancer	6.18e-06	0.000138	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN1B—ovarian cancer	6.15e-06	0.000372	CbGpPWpGaD
Epirubicin—Agranulocytosis—Doxorubicin—ovarian cancer	6.15e-06	0.000137	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.14e-06	0.000137	CcSEcCtD
Epirubicin—Insomnia—Docetaxel—ovarian cancer	6.09e-06	0.000136	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	6.09e-06	0.000368	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—MAPK1—ovarian cancer	6.08e-06	0.000367	CbGpPWpGaD
Epirubicin—Paraesthesia—Docetaxel—ovarian cancer	6.05e-06	0.000135	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—CAV1—ovarian cancer	6.03e-06	0.000365	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	6.03e-06	0.000365	CbGpPWpGaD
Epirubicin—Bradycardia—Doxorubicin—ovarian cancer	6.02e-06	0.000134	CcSEcCtD
Epirubicin—ABCC1—Metabolism—PPP1CC—ovarian cancer	6.02e-06	0.000364	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—BRIP1—ovarian cancer	6.02e-06	0.000364	CbGpPWpGaD
Epirubicin—Dyspnoea—Docetaxel—ovarian cancer	6e-06	0.000134	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—ovarian cancer	6e-06	0.000363	CbGpPWpGaD
Epirubicin—Somnolence—Docetaxel—ovarian cancer	5.99e-06	0.000134	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—ovarian cancer	5.95e-06	0.000133	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—ovarian cancer	5.93e-06	0.000132	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—ovarian cancer	5.93e-06	0.000132	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—ovarian cancer	5.92e-06	0.000132	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—ovarian cancer	5.92e-06	0.000132	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—ovarian cancer	5.89e-06	0.000131	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—ovarian cancer	5.87e-06	0.000131	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CCND1—ovarian cancer	5.87e-06	0.000355	CbGpPWpGaD
Epirubicin—Decreased appetite—Docetaxel—ovarian cancer	5.85e-06	0.000131	CcSEcCtD
Epirubicin—Hypersensitivity—Paclitaxel—ovarian cancer	5.85e-06	0.000131	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—ovarian cancer	5.84e-06	0.00013	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—ovarian cancer	5.83e-06	0.00013	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.81e-06	0.00013	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—ovarian cancer	5.81e-06	0.00013	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—ovarian cancer	5.81e-06	0.00013	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—ovarian cancer	5.8e-06	0.000129	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CD—ovarian cancer	5.78e-06	0.00035	CbGpPWpGaD
Epirubicin—Pain—Docetaxel—ovarian cancer	5.76e-06	0.000129	CcSEcCtD
Epirubicin—Constipation—Docetaxel—ovarian cancer	5.76e-06	0.000129	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	5.74e-06	0.000347	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—ovarian cancer	5.7e-06	0.000127	CcSEcCtD
Epirubicin—Asthenia—Paclitaxel—ovarian cancer	5.7e-06	0.000127	CcSEcCtD
Epirubicin—Pruritus—Paclitaxel—ovarian cancer	5.62e-06	0.000125	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	5.59e-06	0.000338	CbGpPWpGaD
Epirubicin—Erythema multiforme—Doxorubicin—ovarian cancer	5.59e-06	0.000125	CcSEcCtD
Epirubicin—Feeling abnormal—Docetaxel—ovarian cancer	5.55e-06	0.000124	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—ovarian cancer	5.53e-06	0.000123	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—ovarian cancer	5.52e-06	0.000123	CcSEcCtD
Epirubicin—Gastrointestinal pain—Docetaxel—ovarian cancer	5.51e-06	0.000123	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CG—ovarian cancer	5.49e-06	0.000332	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.49e-06	0.000332	CbGpPWpGaD
Epirubicin—Flushing—Doxorubicin—ovarian cancer	5.49e-06	0.000123	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—ovarian cancer	5.49e-06	0.000123	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—IL6—ovarian cancer	5.49e-06	0.000332	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HDAC6—ovarian cancer	5.45e-06	0.000329	CbGpPWpGaD
Epirubicin—Diarrhoea—Paclitaxel—ovarian cancer	5.44e-06	0.000121	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MAPK3—ovarian cancer	5.41e-06	0.000327	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.41e-06	0.000327	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—ovarian cancer	5.37e-06	0.00012	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—ovarian cancer	5.34e-06	0.000119	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—ovarian cancer	5.33e-06	0.000119	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—ovarian cancer	5.32e-06	0.000119	CcSEcCtD
Epirubicin—Abdominal pain—Docetaxel—ovarian cancer	5.32e-06	0.000119	CcSEcCtD
Epirubicin—Chills—Doxorubicin—ovarian cancer	5.31e-06	0.000119	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—ovarian cancer	5.28e-06	0.000118	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.28e-06	0.000319	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.27e-06	0.000319	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—ovarian cancer	5.27e-06	0.000318	CbGpPWpGaD
Epirubicin—Dizziness—Paclitaxel—ovarian cancer	5.25e-06	0.000117	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—ovarian cancer	5.23e-06	0.000117	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—ovarian cancer	5.18e-06	0.000116	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—YAP1—ovarian cancer	5.15e-06	0.000312	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MAPK1—ovarian cancer	5.15e-06	0.000311	CbGpPWpGaD
Epirubicin—Erythema—Doxorubicin—ovarian cancer	5.15e-06	0.000115	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—ovarian cancer	5.15e-06	0.000115	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—ovarian cancer	5.1e-06	0.000308	CbGpPWpGaD
Epirubicin—Flatulence—Doxorubicin—ovarian cancer	5.07e-06	0.000113	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—YAP1—ovarian cancer	5.05e-06	0.000306	CbGpPWpGaD
Epirubicin—Tension—Doxorubicin—ovarian cancer	5.05e-06	0.000113	CcSEcCtD
Epirubicin—Vomiting—Paclitaxel—ovarian cancer	5.05e-06	0.000113	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—ovarian cancer	5.04e-06	0.000113	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CB—ovarian cancer	5.04e-06	0.000305	CbGpPWpGaD
Epirubicin—Rash—Paclitaxel—ovarian cancer	5.01e-06	0.000112	CcSEcCtD
Epirubicin—Dermatitis—Paclitaxel—ovarian cancer	5.01e-06	0.000112	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—ovarian cancer	5e-06	0.000112	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5e-06	0.000302	CbGpPWpGaD
Epirubicin—Back pain—Doxorubicin—ovarian cancer	4.98e-06	0.000111	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	4.98e-06	0.000301	CbGpPWpGaD
Epirubicin—Headache—Paclitaxel—ovarian cancer	4.98e-06	0.000111	CcSEcCtD
Epirubicin—Hypersensitivity—Docetaxel—ovarian cancer	4.96e-06	0.000111	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—ovarian cancer	4.95e-06	0.000111	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—ovarian cancer	4.85e-06	0.000108	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MAPK3—ovarian cancer	4.84e-06	0.000293	CbGpPWpGaD
Epirubicin—Asthenia—Docetaxel—ovarian cancer	4.83e-06	0.000108	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CD—ovarian cancer	4.83e-06	0.000292	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	4.81e-06	0.000291	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Doxorubicin—ovarian cancer	4.78e-06	0.000107	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—HDAC6—ovarian cancer	4.77e-06	0.000289	CbGpPWpGaD
Epirubicin—Pruritus—Docetaxel—ovarian cancer	4.76e-06	0.000106	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—ovarian cancer	4.76e-06	0.000106	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—ovarian cancer	4.73e-06	0.000106	CcSEcCtD
Epirubicin—ABCC1—Disease—XIAP—ovarian cancer	4.72e-06	0.000286	CbGpPWpGaD
Epirubicin—Nausea—Paclitaxel—ovarian cancer	4.72e-06	0.000105	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PPP2R1A—ovarian cancer	4.71e-06	0.000285	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MYC—ovarian cancer	4.71e-06	0.000285	CbGpPWpGaD
Epirubicin—Malaise—Doxorubicin—ovarian cancer	4.64e-06	0.000104	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—ovarian cancer	4.63e-06	0.000103	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—ovarian cancer	4.62e-06	0.000103	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—ovarian cancer	4.61e-06	0.000103	CcSEcCtD
Epirubicin—Diarrhoea—Docetaxel—ovarian cancer	4.61e-06	0.000103	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MAPK1—ovarian cancer	4.61e-06	0.000278	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SMARCA4—ovarian cancer	4.6e-06	0.000278	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCND1—ovarian cancer	4.59e-06	0.000278	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.57e-06	0.000276	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—ovarian cancer	4.55e-06	0.000102	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—ovarian cancer	4.53e-06	0.000101	CcSEcCtD
Epirubicin—Cough—Doxorubicin—ovarian cancer	4.49e-06	0.0001	CcSEcCtD
Epirubicin—ABCC1—Disease—EREG—ovarian cancer	4.49e-06	0.000272	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—ovarian cancer	4.46e-06	9.96e-05	CcSEcCtD
Epirubicin—Dizziness—Docetaxel—ovarian cancer	4.45e-06	9.94e-05	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—ovarian cancer	4.45e-06	9.93e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.4e-06	0.000266	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.39e-06	0.000265	CbGpPWpGaD
Epirubicin—Myalgia—Doxorubicin—ovarian cancer	4.38e-06	9.79e-05	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—ovarian cancer	4.38e-06	9.79e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—ovarian cancer	4.38e-06	9.79e-05	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—ovarian cancer	4.37e-06	9.75e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTEN—ovarian cancer	4.36e-06	0.000263	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.35e-06	9.72e-05	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—ovarian cancer	4.33e-06	9.67e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN1B—ovarian cancer	4.3e-06	0.00026	CbGpPWpGaD
Epirubicin—Dry mouth—Doxorubicin—ovarian cancer	4.29e-06	9.57e-05	CcSEcCtD
Epirubicin—Vomiting—Docetaxel—ovarian cancer	4.28e-06	9.56e-05	CcSEcCtD
Epirubicin—Rash—Docetaxel—ovarian cancer	4.25e-06	9.48e-05	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—ovarian cancer	4.24e-06	9.47e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—ovarian cancer	4.24e-06	9.46e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—YAP1—ovarian cancer	4.23e-06	0.000255	CbGpPWpGaD
Epirubicin—Headache—Docetaxel—ovarian cancer	4.22e-06	9.42e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CB—ovarian cancer	4.21e-06	0.000255	CbGpPWpGaD
Epirubicin—Oedema—Doxorubicin—ovarian cancer	4.2e-06	9.38e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—ovarian cancer	4.2e-06	9.38e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—FASN—ovarian cancer	4.2e-06	0.000254	CbGpPWpGaD
Epirubicin—Infection—Doxorubicin—ovarian cancer	4.18e-06	9.32e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—XIAP—ovarian cancer	4.14e-06	0.00025	CbGpPWpGaD
Epirubicin—Shock—Doxorubicin—ovarian cancer	4.14e-06	9.23e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—SLC5A5—ovarian cancer	4.13e-06	0.00025	CbGpPWpGaD
Epirubicin—Nervous system disorder—Doxorubicin—ovarian cancer	4.12e-06	9.2e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—FASN—ovarian cancer	4.12e-06	0.000249	CbGpPWpGaD
Epirubicin—Thrombocytopenia—Doxorubicin—ovarian cancer	4.12e-06	9.19e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—ovarian cancer	4.11e-06	0.000248	CbGpPWpGaD
Epirubicin—Tachycardia—Doxorubicin—ovarian cancer	4.1e-06	9.16e-05	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—ovarian cancer	4.08e-06	9.11e-05	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	4.07e-06	0.000246	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Doxorubicin—ovarian cancer	4.06e-06	9.07e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—SLC5A5—ovarian cancer	4.05e-06	0.000245	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—YAP1—ovarian cancer	4.04e-06	0.000244	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMARCA4—ovarian cancer	4.03e-06	0.000244	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—ovarian cancer	4.01e-06	8.94e-05	CcSEcCtD
Epirubicin—Nausea—Docetaxel—ovarian cancer	4e-06	8.93e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4e-06	0.000242	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SLC2A1—ovarian cancer	3.99e-06	0.000241	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EREG—ovarian cancer	3.94e-06	0.000238	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FASN—ovarian cancer	3.93e-06	0.000238	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—ovarian cancer	3.93e-06	8.77e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—PARP1—ovarian cancer	3.91e-06	0.000237	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SLC2A1—ovarian cancer	3.91e-06	0.000237	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—ovarian cancer	3.87e-06	0.000234	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IL2—ovarian cancer	3.87e-06	0.000234	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.83e-06	0.000232	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.83e-06	8.55e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CYP1B1—ovarian cancer	3.83e-06	0.000231	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—ovarian cancer	3.8e-06	8.49e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	3.79e-06	0.000229	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—ovarian cancer	3.77e-06	8.43e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CYP1B1—ovarian cancer	3.75e-06	0.000227	CbGpPWpGaD
Epirubicin—Dyspnoea—Doxorubicin—ovarian cancer	3.75e-06	8.37e-05	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—ovarian cancer	3.74e-06	8.34e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—SLC2A1—ovarian cancer	3.73e-06	0.000226	CbGpPWpGaD
Epirubicin—Dyspepsia—Doxorubicin—ovarian cancer	3.7e-06	8.26e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PGR—ovarian cancer	3.69e-06	0.000223	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—ovarian cancer	3.68e-06	0.000223	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—ovarian cancer	3.65e-06	8.16e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.63e-06	8.1e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—ovarian cancer	3.62e-06	8.09e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	3.6e-06	0.000218	CbGpPWpGaD
Epirubicin—Pain—Doxorubicin—ovarian cancer	3.59e-06	8.02e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—ovarian cancer	3.59e-06	8.02e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.51e-06	0.000212	CbGpPWpGaD
Epirubicin—Feeling abnormal—Doxorubicin—ovarian cancer	3.46e-06	7.73e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.44e-06	7.67e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PARP1—ovarian cancer	3.43e-06	0.000207	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPP2R1A—ovarian cancer	3.39e-06	0.000205	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MAPK3—ovarian cancer	3.39e-06	0.000205	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—ovarian cancer	3.34e-06	7.45e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—PPP2R1A—ovarian cancer	3.33e-06	0.000201	CbGpPWpGaD
Epirubicin—Body temperature increased—Doxorubicin—ovarian cancer	3.32e-06	7.42e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—ovarian cancer	3.32e-06	7.42e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.31e-06	0.0002	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—ovarian cancer	3.29e-06	0.000199	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—FASN—ovarian cancer	3.29e-06	0.000199	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—ovarian cancer	3.29e-06	0.000199	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6ST—ovarian cancer	3.28e-06	0.000198	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—NRAS—ovarian cancer	3.25e-06	0.000196	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SLC5A5—ovarian cancer	3.24e-06	0.000196	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MAPK1—ovarian cancer	3.22e-06	0.000195	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PPP2R1A—ovarian cancer	3.17e-06	0.000192	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—ovarian cancer	3.15e-06	0.000191	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ABCB1—ovarian cancer	3.15e-06	0.00019	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SLC2A1—ovarian cancer	3.13e-06	0.000189	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—MAPK3—ovarian cancer	3.11e-06	0.000188	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—ovarian cancer	3.1e-06	6.91e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—TYMS—ovarian cancer	3.09e-06	0.000187	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ABCB1—ovarian cancer	3.09e-06	0.000187	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CA—ovarian cancer	3.07e-06	0.000186	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.06e-06	0.000185	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TYMS—ovarian cancer	3.03e-06	0.000183	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—ovarian cancer	3.02e-06	6.73e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP1B1—ovarian cancer	3e-06	0.000181	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—ovarian cancer	2.97e-06	6.64e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—MAPK1—ovarian cancer	2.96e-06	0.000179	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—ovarian cancer	2.88e-06	6.42e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—KRAS—ovarian cancer	2.79e-06	0.000169	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PPP2R1A—ovarian cancer	2.78e-06	0.000168	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—ovarian cancer	2.78e-06	6.21e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—ovarian cancer	2.77e-06	0.000168	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—ovarian cancer	2.7e-06	0.000164	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—ovarian cancer	2.67e-06	5.97e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—PPP2R1A—ovarian cancer	2.66e-06	0.000161	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—ovarian cancer	2.65e-06	5.92e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—ovarian cancer	2.65e-06	5.91e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.65e-06	0.00016	CbGpPWpGaD
Epirubicin—Headache—Doxorubicin—ovarian cancer	2.63e-06	5.88e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—ovarian cancer	2.57e-06	0.000155	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—ovarian cancer	2.52e-06	0.000152	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—ovarian cancer	2.51e-06	0.000152	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—ovarian cancer	2.5e-06	5.57e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CAV1—ovarian cancer	2.49e-06	0.000151	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—ovarian cancer	2.48e-06	0.00015	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ABCB1—ovarian cancer	2.47e-06	0.000149	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CAV1—ovarian cancer	2.45e-06	0.000148	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TYMS—ovarian cancer	2.42e-06	0.000147	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—ovarian cancer	2.42e-06	0.000146	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—ovarian cancer	2.37e-06	0.000144	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.34e-06	0.000141	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CAV1—ovarian cancer	2.33e-06	0.000141	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—ovarian cancer	2.32e-06	0.00014	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CG—ovarian cancer	2.27e-06	0.000137	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—ovarian cancer	2.23e-06	0.000135	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—ovarian cancer	2.22e-06	0.000134	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6ST—ovarian cancer	2.21e-06	0.000134	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—ovarian cancer	2.21e-06	0.000134	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APC—ovarian cancer	2.13e-06	0.000128	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—ovarian cancer	2.1e-06	0.000127	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CAV1—ovarian cancer	2.04e-06	0.000124	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—ovarian cancer	2e-06	0.000121	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—ovarian cancer	1.97e-06	0.000119	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—ovarian cancer	1.96e-06	0.000118	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CAV1—ovarian cancer	1.95e-06	0.000118	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6ST—ovarian cancer	1.94e-06	0.000117	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—ovarian cancer	1.87e-06	0.000113	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.87e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—ovarian cancer	1.86e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APC—ovarian cancer	1.86e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—ovarian cancer	1.86e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK3—ovarian cancer	1.78e-06	0.000108	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—ovarian cancer	1.78e-06	0.000108	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—ovarian cancer	1.74e-06	0.000105	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—ovarian cancer	1.71e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK1—ovarian cancer	1.7e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—ovarian cancer	1.7e-06	0.000103	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—ovarian cancer	1.65e-06	9.98e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—ovarian cancer	1.64e-06	9.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—ovarian cancer	1.63e-06	9.84e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTOR—ovarian cancer	1.63e-06	9.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—ovarian cancer	1.6e-06	9.69e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—ovarian cancer	1.56e-06	9.46e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1B—ovarian cancer	1.53e-06	9.24e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—ovarian cancer	1.5e-06	9.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—ovarian cancer	1.47e-06	8.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—ovarian cancer	1.47e-06	8.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—ovarian cancer	1.45e-06	8.74e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—ovarian cancer	1.44e-06	8.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—ovarian cancer	1.43e-06	8.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MTOR—ovarian cancer	1.43e-06	8.63e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—ovarian cancer	1.41e-06	8.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—ovarian cancer	1.37e-06	8.29e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—ovarian cancer	1.36e-06	8.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—ovarian cancer	1.36e-06	8.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1B—ovarian cancer	1.34e-06	8.1e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—ovarian cancer	1.31e-06	7.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—ovarian cancer	1.31e-06	7.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—ovarian cancer	1.3e-06	7.88e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—ovarian cancer	1.28e-06	7.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—ovarian cancer	1.27e-06	7.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—ovarian cancer	1.26e-06	7.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—ovarian cancer	1.26e-06	7.59e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—ovarian cancer	1.24e-06	7.5e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—ovarian cancer	1.23e-06	7.46e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—ovarian cancer	1.2e-06	7.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK3—ovarian cancer	1.2e-06	7.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—ovarian cancer	1.18e-06	7.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—ovarian cancer	1.17e-06	7.07e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK1—ovarian cancer	1.14e-06	6.92e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—ovarian cancer	1.14e-06	6.91e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—ovarian cancer	1.11e-06	6.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—ovarian cancer	1.1e-06	6.67e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—ovarian cancer	1.1e-06	6.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—ovarian cancer	1.08e-06	6.53e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—ovarian cancer	1.06e-06	6.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK3—ovarian cancer	1.05e-06	6.37e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—ovarian cancer	1.04e-06	6.29e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—ovarian cancer	1.02e-06	6.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK1—ovarian cancer	1e-06	6.06e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—ovarian cancer	1e-06	6.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—ovarian cancer	9.93e-07	6e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—ovarian cancer	9.47e-07	5.73e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—ovarian cancer	9.18e-07	5.55e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—ovarian cancer	8.79e-07	5.31e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—ovarian cancer	8.7e-07	5.26e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—ovarian cancer	8.67e-07	5.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—ovarian cancer	8.5e-07	5.14e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—ovarian cancer	8.42e-07	5.09e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—ovarian cancer	8.31e-07	5.03e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—ovarian cancer	8.11e-07	4.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—ovarian cancer	8.05e-07	4.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—ovarian cancer	7.7e-07	4.66e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—ovarian cancer	7.11e-07	4.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—ovarian cancer	6.79e-07	4.11e-05	CbGpPWpGaD
